Loading organizations...
§ Private Profile · Taipei, T'ai-pei, Taiwan
Cancer genomics company providing molecular profiling and genomic testing services for precision oncology, guiding personalized treatment.
Based in Taipei, Taiwan, ACT Genomics provides cancer molecular information services and next-generation sequencing to guide precision oncology treatments. The company analyzes tumor genomic alterations across over 400 cancer-related genes to help oncologists match patients with targeted therapies and immunotherapies. Operating across the Asia-Pacific region and the United Kingdom, the firm generates revenue by selling clinical genomic tests to healthcare providers and offering specialized biomarker testing services to global biopharmaceutical companies. After raising $8 million in its initial private funding round, the enterprise expanded its regional footprint by merging with the Hong Kong-based diagnostics company Sanomics in 2021. In December 2022, the health and genetics company Prenetics acquired a majority stake in the business, which is chaired by Tony Mok. ACT Genomics was founded in 2014 by Hua Chien Chen, Shu-Jen Chen, and Pei-Li Kao.
ACT Genomics has raised $12.5M across 1 funding round.
ACT Genomics has raised $12.5M in total across 1 funding round.
ACT Genomics has raised $12.5M in total across 1 funding round.
ACT Genomics's investors include CDIB Capital, Hotung Venture Group, Eminent II Venture Capital, Hua Nan Venture Capital, President International Development Corporation, UMC Capital.
ACT Genomics has raised $12.5M across 1 funding round. Most recently, it raised $12.5M Series B in May 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 6, 2016 | $12.5M Series B | Cdib Capital, Hotung Venture Group | Eminent II Venture Capital, HUA NAN Venture Capital, President International Development Corporation, UMC Capital | Announced |